MedPath

Post-trial Access Program of Idursulfase-IT Along With Elaprase in Children With Hunter Syndrome

Conditions
Hunter Syndrome
Registration Number
NCT05795361
Lead Sponsor
Takeda
Brief Summary

As the HGT-HIT-046 (NCT01506141) and SHP609-302 (NCT02412787) studies will be closed, this post-trial access (PTA) program provides TAK-609 to participants in these studies for whom the benefit:risk ratio of continued treatment with idursulfase-IT remains positive.

Detailed Description

Not available

Recruitment & Eligibility

Status
AVAILABLE
Sex
Male
Target Recruitment
Not specified
Inclusion Criteria
  1. Participants will have completed the treatment period of the HGT-HIT-046 (NCT01506141) or SHP609-302 (NCT02412787) study prior to the first dose on this program.
  2. Participant and/or a parent(s)/legal guardian is informed of the nature of this compassionate post-trial access program and can provide written informed consent for themselves or the child to participate (with assent from the child when appropriate prior to treatment).
Read More
Exclusion Criteria
  1. Participant has a condition that in the opinion of the treating physician may compromise their safety.
  2. Participant has a known hypersensitivity to idursulfase-IT or its components.
Read More

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (28)

Childrens Hospital Orange County

๐Ÿ‡บ๐Ÿ‡ธ

Anaheim, California, United States

The Children's Hospital of Philadelphia

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

The Regents of the University of California

๐Ÿ‡บ๐Ÿ‡ธ

Oakland, California, United States

Phoenix Childrens Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Phoenix, Arizona, United States

The Cleveland Clinic Foundation

๐Ÿ‡บ๐Ÿ‡ธ

Cleveland, Ohio, United States

UPMC Childrens Hospital of Pittsburgh

๐Ÿ‡บ๐Ÿ‡ธ

Pittsburgh, Pennsylvania, United States

Randall Children's Hospital at Legacy Emanuel

๐Ÿ‡บ๐Ÿ‡ธ

Portland, Oregon, United States

Children's Hospital Colorado

๐Ÿ‡บ๐Ÿ‡ธ

Aurora, Colorado, United States

The Nemours Foundation

๐Ÿ‡บ๐Ÿ‡ธ

Wilmington, Delaware, United States

Washington University

๐Ÿ‡บ๐Ÿ‡ธ

Washington, Missouri, United States

The University of North Carolina

๐Ÿ‡บ๐Ÿ‡ธ

Chapel Hill, North Carolina, United States

Jackson Memorial Hospital University of Miami

๐Ÿ‡บ๐Ÿ‡ธ

Miami, Florida, United States

Ann and Robert H Lurie Childrens Hospital of Chicago

๐Ÿ‡บ๐Ÿ‡ธ

Chicago, Illinois, United States

Board of Regents of the University of Nebraska

๐Ÿ‡บ๐Ÿ‡ธ

Omaha, Nebraska, United States

NYU Langone Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

New York, New York, United States

Joseph M. Sanzari Children's Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Hackensack, New Jersey, United States

Royal Manchester Children's Hospital - PPDS

๐Ÿ‡ฌ๐Ÿ‡ง

Manchester, United Kingdom

Vanderbilt Children's Hospital

๐Ÿ‡บ๐Ÿ‡ธ

Nashville, Tennessee, United States

Texas Oncology P.A

๐Ÿ‡บ๐Ÿ‡ธ

Dallas, Texas, United States

Birmingham Womens and ChildrensNHS Foundation Trust

๐Ÿ‡ฌ๐Ÿ‡ง

Birmingham, United Kingdom

Universtity College London Hospital

๐Ÿ‡ฌ๐Ÿ‡ง

London, United Kingdom

Division of Medical Genetics, University of Utah

๐Ÿ‡บ๐Ÿ‡ธ

Salt Lake City, Utah, United States

Seattle Children's Hospital - PIN

๐Ÿ‡บ๐Ÿ‡ธ

Seattle, Washington, United States

H.C.U. de Valladolid

๐Ÿ‡ฒ๐Ÿ‡ฝ

Valladolid, Mexico

Queensland Childrens Hospital

๐Ÿ‡ฆ๐Ÿ‡บ

South Brisbane, Queensland, Australia

Instituto Nacional de Pediatria

๐Ÿ‡ฒ๐Ÿ‡ฝ

Coyoacan, Ciudad De Mexico, Mexico

Hospital 12 de Octubre

๐Ÿ‡ช๐Ÿ‡ธ

Usera, Madrid, Spain

Hospital Universitario Reina Sofia

๐Ÿ‡ช๐Ÿ‡ธ

Cordoba, Spain

ยฉ Copyright 2025. All Rights Reserved by MedPath